R&G PharmaStudies Co., Ltd. (SHE:301333)
China
· Delayed Price · Currency is CNY 64.99
-1.20 (-1.81%)
At close: Mar 9, 2026
R&G PharmaStudies Revenue
R&G PharmaStudies had revenue of 227.71M CNY in the quarter ending September 30, 2025, with 24.48% growth. This brings the company's revenue in the last twelve months to 789.45M, up 4.06% year-over-year. In the year 2024, R&G PharmaStudies had annual revenue of 744.00M with 3.14% growth.
Revenue (ttm)
789.45M
Revenue Growth
+4.06%
P/S Ratio
7.83
Revenue / Employee
357.54K
Employees
2,208
Market Cap
6.18B
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GemPharmatech | 793.25M |
| Xiangxue Pharmaceutical | 1.47B |
| Shanghai OPM Biosciences | 354.91M |
| Beijing Konruns Pharmaceutical | 871.31M |
| Lifecome Biochemistry | 587.04M |
| Kexing Biopharm | 1.54B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Shouyao Holdings (Beijing) Co., LTD. | 8.67M |